Literature DB >> 10642307

Angiotensin II and PDGF-BB stimulate beta(1)-integrin-mediated adhesion and spreading in human VSMCs.

K Kappert1, G Schmidt, G Doerr, B Wollert-Wulf, E Fleck, K Graf.   

Abstract

beta(1)-Integrins play an important role for adhesion and spreading of human smooth muscle cells. In the present study we examined the influence of angiotensin II and platelet-derived growth factor (PDGF)-BB on beta(1)-integrin-dependent functions of human smooth muscle cells obtained from iliac arteries. Treatment of these cells with PDGF-BB (20 ng/mL) and Angiotensin II (1 micromol/L) did not change beta(1)-integrin expression up to 48 hours as analyzed by flow cytometry and reverse transcription polymerase chain reaction. beta(1)-integrins predominantly mediated adhesion of human smooth muscle cells to collagen I (79.7+/-4.4%, P<0.01) and fibronectin (66. 6+/-2.4%, P<0.01). Treatment of smooth muscle cells with Angiotensin II (1 micromol/L) and PDGF-BB (20 ng/mL) significantly increased the adhesion to collagen I by 56.5% and 44.3%, respectively, and to fibronectin by 49.6% and 36.4%, respectively (all P<0.05). Angiotensin II-induced effects were mediated by the AT(1) receptor. The PDGF-BB mediated increase of adhesion was inhibited in the presence of genestein, a tyrosine-kinase inhibitor and by protein kinase C downregulation with phorbol 12-myristate 13-acetate. Spreading of smooth muscle cells also was beta(1)-integrin dependent on collagen I and alpha(5)beta(1)-integrin dependent on fibronectin. Angiotensin II and PDGF-BB increased cell spreading on fibronectin up to 276% and 318%, respectively, and on collagen I up to 133% and 138% (all P<0.05). These increases were significantly inhibited by blocking antibodies against beta(1)-integrin, alpha(5)-integrin on fibronectin, the AT(1) receptor blocker irbesartan, and genestein. The present data demonstrate that angiotensin II and as well PDGF-BB enhance beta(1)-integrin-dependent adhesion and spreading of human vascular smooth muscle cells. Furthermore, the experiments with PDGF suggest an involvement of protein kinase C activation leading to these enhanced effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10642307     DOI: 10.1161/01.hyp.35.1.255

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  6 in total

1.  Substrate-induced phenotypic switches of human smooth muscle cells: an in vitro study of in-stent restenosis activation pathways.

Authors:  Anna L Guildford; Helen J S Stewart; Christopher Morris; Matteo Santin
Journal:  J R Soc Interface       Date:  2010-11-24       Impact factor: 4.118

2.  Reduced stiffness and augmented traction force in type 2 diabetic coronary microvascular smooth muscle.

Authors:  Patricia E McCallinhart; Youjin Cho; Zhe Sun; Samir Ghadiali; Gerald A Meininger; Aaron J Trask
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-05-01       Impact factor: 4.733

3.  Biomechanical Strain Exacerbates Inflammation on a Progeria-on-a-Chip Model.

Authors:  João Ribas; Yu Shrike Zhang; Patrícia R Pitrez; Jeroen Leijten; Mario Miscuglio; Jeroen Rouwkema; Mehmet Remzi Dokmeci; Xavier Nissan; Lino Ferreira; Ali Khademhosseini
Journal:  Small       Date:  2017-02-17       Impact factor: 13.281

Review 4.  Integrin signaling in atherosclerosis.

Authors:  Alexandra C Finney; Karen Y Stokes; Christopher B Pattillo; A Wayne Orr
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

5.  Role of integrins in angiotensin II-induced proliferation of vascular smooth muscle cells.

Authors:  Marlene A Bunni; Inga I Kramarenko; Linda Walker; John R Raymond; Maria N Garnovskaya
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-09       Impact factor: 4.249

6.  Cellular polarity modulates drug resistance in primary colorectal cancers via orientation of the multidrug resistance protein ABCB1.

Authors:  Neil Ashley; Djamila Ouaret; Walter F Bodmer
Journal:  J Pathol       Date:  2019-01-16       Impact factor: 7.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.